StockMarketWire.com - Pharmaceutical company Diurnal Group said its application for market authorisation for its congenital adrenal hyperplasia treatment was recently granted Orphan Drug Designation in Australia.

The application was filed on by the company's marketing and distribution partner in Australia and New Zealand, Emerge Health.

'We look forward to developing our already successful relationship with Emerge Health as we continue to build our marketing and distribution capabilities in high-value markets outside our core territories,' the company said.

The Orphan Drug Designation is a valuable regulatory privilege that provides significant benefits, including waiver of application, evaluation and annual registration fees.




At 9:18am: [LON:DNL] Diurnal Group Plc share price was +1p at 30.5p



Story provided by StockMarketWire.com